Ambar Qavi

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

François Venter, Michelle Moorhouse, Simiso Sokhela et al. · New England Journal of Medicine · 2019 · 717 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

François Venter, Simiso Sokhela, Bryony Simmons et al. · The Lancet HIV · 2020 · 260 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Anahita Sadeghı, Ali Asgari, Alireza Norouzi et al. · Journal of Antimicrobial Chemotherapy · 2020 · 132 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes

Kaitlyn McCann, Shahini Shah, Laura Hindley et al. · AIDS · 2021 · 71 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana et al. · Clinical Infectious Diseases · 2022 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16